September 12th 2024
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Precision Medicine Stakes Claim in the Gastrointestinal Stromal Tumors Landscape
March 9th 2021In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.
Read More
Adjuvant Imatinib Confirmed Beneficial for RFS in High-Risk Gastrointestinal Stromal Tumors
February 20th 2021Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.
Read More
Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows
February 19th 2021Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.
Read More
Expert Speaks to Impact of COVID-19 in the Community Oncology Setting, Vaccine Excites Field
December 16th 2020In an interview with Targeted Oncology, Michael J. Wagner, MD, discussed findings from a single-center experience in Seattle managing patients with sarcoma during the COVID-19 pandemic.
Read More
Novel Agent ADP-A2M4 Elicits Durable Response in Synovial Sarcoma
November 24th 2020The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.
Read More
Phase 1 Trial Exhibits Positive Interim Results in Chondrosarcoma
November 13th 2020Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.
Read More
Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma
September 21st 2020Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.
Read More
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes
September 21st 2020Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Ewing Sarcoma May Benefit From Regorafenib Therapy
September 20th 2020As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.
Read More
Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS
June 2nd 2020Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Watch
Patients With Pretreated Sarcoma May Derive Benefit From Various Immunotherapy Combinations
April 15th 2020Combination therapy strategies involving immune checkpoint inhibitors and a secondary agent have shown promise across sarcoma subtypes, according to analysis of clinical trial data that were presented at the European Society for Medical Oncology Sarcoma & GIST Symposium 2020, held in Milan, Italy.
Read More
Cabozantinib May Be a New Therapeutic Option for Ewing Sarcoma and Osteosarcoma
April 3rd 2020Cabozantinib demonstrated antitumor activity as treatment of patients with advanced Ewing sarcoma and osteosarcoma, warranting further investigation for a potential new therapeutic option for this patient population, according to findings from phase II CABONE study.
Read More
Genetic Profiling Suggests Rationale for Limited Response to Immunotherapy in Osteosarcoma
February 22nd 2020Treatment with immune checkpoint inhibitors appears to elicit limited clinical activity in patients with osteosarcoma. In a study, investigators at MD Anderson Cancer Center found that certain factors like poor infiltration of the tumor by immune cells, low activity from available T cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways may interfere with response to immunotherapy in these patients, according to a press release from the organization.<br />
Read More
A Look Back at FDA News from January 2020
February 8th 2020In January 2020, the FDA approved new treatment options in gastrointestinal stromal tumors, bladder cancer, and epithelioid sarcoma. The FDA also granted several Priority Review Designations, orphan drug designations, and a Fast Track designation, as well as a Breakthrough Therapy designation.
Read More
Immunotherapy Combination Induces Promising ORR in Patients With Advanced Sarcoma
February 5th 2020The combination of talimogene laherparepvec plus pembrolizumab led to a promising objective response rate in patients with advanced sarcoma who typically have limited treatment options, according to a phase II clinical trial published in <em>JAMA Oncology</em>.
Read More
HER2-Directed CAR T-Cell Therapy Appears Active in Phase I Trial for Advanced Sarcoma
February 2nd 2020In an interview with Targeted Oncology, Shoba A. Navai, MD, discussed the evolving role of CAR T-cell therapy in solid tumors, including sarcomas and how the efficacy and safety compare with CAR T cells in this space compared with hematologic malignancies.
Read More